The EPS beat is positive but cash depletion and widening operating burn suggest dilution or partnership risk within 2-3 quarters. Watch for secondary offering or licensing deal to extend runway, and for interim OVATION 3 data updates.
Price Chart
Executive Summary
Imunon reported Q1 2026 GAAP EPS of -$0.84, beating consensus of -$0.99 by 15%, but operating cash burn widened to -$4.0M and cash fell to $4.8M. Clinical progress on IMNN-001's Phase 3 OVATION 3 trial continues, with FDA alignment on the protocol, but the financials highlight a tightening cash runway.
Key Financial Metrics
Key Facts
- Q1 2026 GAAP EPS -$0.84 vs consensus -$0.99 (beat by 15.2%)
- Net loss $4.3M vs $4.1M in Q1 2025; operating expenses flat at $4.3M
- Cash and equivalents $4.8M at Mar 31, 2026, down from $8.8M at Dec 31, 2025
- Operating cash flow -$4.0M vs -$2.8M in prior year quarter
- Phase 3 OVATION 3 enrollment expected to complete by Q1 2029; FDA aligned on protocol
- Strategic reorganization completed Feb 2026 to reduce operating expenses
Financial Impact
EPS beat of $0.15 per share vs consensus, but cash burn accelerated by $1.2M YoY; cash runway ~8 months at current burn
Risk Factors
- Cash runway insufficient to complete Phase 3 enrollment without additional financing
- No approved products; clinical trial failure would be existential
- High stock volatility typical of micro-cap biotech
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-022401 |
| Document: form8-k.htm | 0001493152-26-022401 |
| Document: 0001493152-26-022401-index-headers.html | 0001493152-26-022401 |
| Document: 0001493152-26-022401-index.html | 0001493152-26-022401 |
| Document: 0001493152-26-022401.txt | 0001493152-26-022401 |
| 8-K Data (Synthetic) | 0001493152-26-022401 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | S-1 | $1.22 | awaiting T+5 | — | $1.01 (+17.22%) |
Oct 27, 2026 today | 8-K | $1.25 | awaiting T+5 | — | $1.01 (−19.21%) |
Oct 21, 2026 6d ago | 8-K | $1.19 | awaiting T+5 | — | $1.01 (−15.13%) |
Sep 29, 2026 28d ago | 8-K | $1.34 $1.12 | ▲ +16.10% | ▲ +18.05% | $1.01 (+24.35%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.42% | $1.01 (−37.27%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.46% | $1.01 (−37.27%) |
Jun 30, 2026 16w ago | 8-K | $1.88 $1.95 | ▲ +3.72% | ▲ +3.46% | $1.01 (−46.28%) |
Jun 16, 2026 18w ago | 8-K | $1.86 $1.73 | ▼ −6.99% | ▼ −5.95% | $1.01 (−45.70%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $2.03 | ▲ +3.33% | ▲ +0.78% | $1.01 (+51.91%) |
May 12, 2026 24w ago | 8-K | $2.70 $2.26 | ▼ −16.30% | ▼ −16.37% | $1.01 (−62.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers